Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary
Singapore medical journal
; : e269-71, 2012.
Article
em En
| WPRIM
| ID: wpr-335474
Biblioteca responsável:
WPRO
ABSTRACT
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Pessários
/
Recidiva
/
Candidíase Vulvovaginal
/
Tratamento Farmacológico
/
Imidazóis
/
Antifúngicos
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Singapore medical journal
Ano de publicação:
2012
Tipo de documento:
Article